Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer

Mario E. Lacouture*, Kathryn Ciccolini, Richard T. Kloos, Mark Agulnik

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations

Abstract

Background: Treatment options for patients with advanced or metastatic medullary thyroid cancer (MTC) have, in recent years, expanded with the approval of two tyrosine kinase inhibitors (TKIs): vandetanib and cabozantinib. Other agents, including TKIs, are under clinical investigation for MTC. Although patients treated with TKIs are at risk of developing dermatologic adverse events (AE), these untoward eventsmay be mitigated throughAE-driven algorithms. Summary: AE-driven algorithms combine effective nonpharmaceutical and pharmaceutical treatment modalities implemented by a multidisciplinary effort that incorporates nursing interventions, patient education, and referrals to pain-management specialists, podiatrists, and dermatologists, as appropriate.EffectiveAEprevention and management reduce the need for dose interruptions andmodifications, allowing patients the opportunity to derive themaximal benefit from TKI therapy, while maintaining quality of life. Conclusions: Optimal use of targeted therapies in the treatment of MTC depends on careful patient selection, interdisciplinary communication, and patient education and encouragement to enhance compliance and safety, optimize consistent dosing, and maximize the use of effective therapies.

Original languageEnglish (US)
Pages (from-to)1329-1340
Number of pages12
JournalThyroid
Volume24
Issue number9
DOIs
StatePublished - Sep 1 2014

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer'. Together they form a unique fingerprint.

Cite this